About HizentraSCIg TherapyIdentifying PatientsHizentra and VivaglobinEfficacySafety and TolerabilityAdverse ReactionsDosage and AdministrationInitiating HizentraAssistance and SupportSHARE Nurse Training and ExamInfusion Support CenterProfessional ResourcesFrequently Asked QuestionsRequest More InformationImportant Safety Information

Which Ig therapy is right for your patient?

Research studies and experience have identified certain patient characteristics that may indicate which individuals may be suitable for either SCIg therapy or IVIg treatment.3 These characteristics can be found here.

Patient characteristics for PIDD treatments3
Subcutaneous Ig (SCIg)
therapy 		Intravenous (IVIg) therapy
Patients or families with active lifestyles, full-time work/school routines, or busy family schedules Patients who look forward to their IVIg appointments or for whom a trip to the infusion clinic or a visit from the home care nurse is an important part of their social lives
Patients who prefer the freedom, flexibility, and autonomy of self-administration Patients who don't want to receive their Ig therapy more than every 3 to 4 weeks
Patients for whom a sharp increase in serum IgG levels during or after an IVIg infusion causes systemic adverse reactions Patients who tolerate their IV therapy with minimal adverse reactions
Patients with poor venous access Patients with good venous access
Patients who prefer to manage their own health Patients who prefer the one-on-one care provided by a healthcare professional
Patients who have a clear understanding of SCIg therapy Patients who are unclear about the concept of SCIg therapy
 

Click here for a printer-friendly version of this chart

Safety and tolerability

In the clinical trial, Hizentra was shown to be safe, with demonstrated tolerability.

View safety profile

Protection against infection

SCIg therapy with Hizentra was shown to be effective

View efficacy results

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritis, vomiting, upper abdominal pain, pain, and migraine.

Monitor patients for thrombotic events and aseptic meningitis (AMS), which have been reported with SCIg. Also look forreactions reported to occur with IVIg treatment that might also occur with Hizentra, including renal dysfunction/failure, hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please see full prescribing information for Hizentra.